Patent ID: 7538185

Claim:
A GLP-1 analog comprising the following sequence: R1-His-X8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-X20-Glu-Gly-Gln-Ala-Ala-Lys-X27-Phe-Ile-X30-Trp-Leu-X33 (SEQ ID NOs: 1 to 11, depending on the nature of X33) wherein: (i) R1 is 2-hydroxybenzoyl or hydrogen; X8 is Ala or Gly; X20 is selected from the group consisting of Leu and Gly having a C 6 -C 20 alkyl side chain; X27 is Ala or Leu; X30 is Glu or Gln, and X33 is Val-Lys-Asn-NH 2 ; or (ii) R1 is 2-hydroxybenzoyl or hydrogen; X8 is Ala or Gly; X20 is selected from the group consisting of Leu and Gly having a C 6 -C 20 alkyl side chain; X27 is Ala or Leu; X30 is Glu; and X33 is Lys-Asn-NH 2 ; or (iii) R1 is 2-hydroxybenzoyl, trans-3-hexenoyl or hydrogen; X8 is Ala or Gly; X20 is selected from the group consisting of Leu and Gly having a C 6 C 20 alkyl side chain; X27 is Leu; X30 is Glu; and X33 is Lys-Asn-Aib-NH 2 ; or (iv) R1 is trans-3-hexenoyl or hydrogen; X8 is Ala or Gly; X20 is selected from the group consisting of Leu and Gly having a C 6 -C 20 alkyl side chain; X27 is Ala or Leu; X30 is Glu; and X33 is Lys-Asn-NH 2 ; or (v) R1 is trans-3-hexenoyl or hydrogen; X8 is Ala or Gly; X20 is (S)-Octylglycine; X27 is Ala or Leu; X30 is Glu, Gln or Asp; and X33 is Lys-Asn-NH 2 or Val-Lys-Asn-NH 2 ; or (vi) the GLP-1 analog has a sequence selected from the group consisting of: SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO: 20; SEQ ID NO: 21; SEQ ID NO: 22; SEQ ID NO: 23; SEQ ID NO:24; SEQ ID NO: 25; SEQ ID NO:26, SEQ ID NO: 27, SEQ ID NO:28, SEQ ID NO: 29; SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32; SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 35, SEQ ID NO:36, AND SEQ ID NO: 38.